
|Articles|July 9, 2014
- Hematologic Malignancies
- Volume 1
- Issue 1
Comorbidities, Age, and Outcomes Among Intensively Treated Patients With AML
Author(s)Timothy S. Pardee, MD
Timothy S. Pardee, MD, discusses comorbidities, age, and outcomes among intensively treated patients with acute myeloid leukemia (AML).
Advertisement
Timothy S. Pardee, MD, assistant professor, Hematology & Oncology, Wake Forest University Baptist Medical Center, discusses comorbidities, age, and outcomes among intensively treated patients with acute myeloid leukemia (AML).
Read about new treatments for AML > >
Articles in this issue
over 11 years ago
In the Pipeline: Potential New Treatments for AMLover 11 years ago
Epidemiology in B-Cell Malignanciesover 11 years ago
Pathogenesis of Follicular Lymphomaover 11 years ago
Resistance to Ibrutinibover 11 years ago
IPI-145 and ABT-199 for Lymphoid Malignanciesover 11 years ago
BCL-2 Inhibitor Combo May Offer Remissions in CLLAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5








































